American biotech firm Biogen (Nasdaq: BIIB) has acquired from Bristol-Myers Squibb (NYSE: BMY) an exclusive license for BMS-986168, a therapy candidate in Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP).
Biogen plans to begin Phase II studies in both AD and PSP for the antibody, which targets ‘extracellular tau’, a protein associated with these conditions.
The company will receive worldwide rights to the candidate and will be responsible for full development and global commercialization in these therapy areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze